SG50585A1 - Glycoalkaloids - Google Patents

Glycoalkaloids

Info

Publication number
SG50585A1
SG50585A1 SG1996005588A SG1996005588A SG50585A1 SG 50585 A1 SG50585 A1 SG 50585A1 SG 1996005588 A SG1996005588 A SG 1996005588A SG 1996005588 A SG1996005588 A SG 1996005588A SG 50585 A1 SG50585 A1 SG 50585A1
Authority
SG
Singapore
Prior art keywords
cells
abnormal
cellular
removal
normal
Prior art date
Application number
SG1996005588A
Other languages
English (en)
Inventor
Bill Elliot Cham
Brian Daunter
Original Assignee
Cura Nominees Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cura Nominees Pty Ltd filed Critical Cura Nominees Pty Ltd
Publication of SG50585A1 publication Critical patent/SG50585A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0042—Nitrogen only
    • C07J71/0052—Nitrogen only at position 16(17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0057—Nitrogen and oxygen
    • C07J71/0068—Nitrogen and oxygen at position 16(17)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/14—Topical contraceptives and spermacides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
SG1996005588A 1990-01-18 1991-01-18 Glycoalkaloids SG50585A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPJ824390 1990-01-18

Publications (1)

Publication Number Publication Date
SG50585A1 true SG50585A1 (en) 1998-07-20

Family

ID=3774458

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996005588A SG50585A1 (en) 1990-01-18 1991-01-18 Glycoalkaloids

Country Status (11)

Country Link
US (1) US5958770A (fr)
EP (1) EP0515386B1 (fr)
JP (1) JP3168542B2 (fr)
KR (1) KR100213805B1 (fr)
AT (1) ATE188036T1 (fr)
AU (1) AU654474B2 (fr)
BR (1) BR9105952A (fr)
CA (1) CA2073855C (fr)
DE (1) DE69131861T2 (fr)
SG (1) SG50585A1 (fr)
WO (1) WO1991010743A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004556A1 (fr) * 1992-08-21 1994-03-03 New York University Aminofurostenes, compositions, et procedes d'utilisation
GB9618119D0 (en) * 1996-08-30 1996-10-09 Univ Southampton Adjuvants for use in vaccines
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
EP1066033B1 (fr) * 1998-03-26 2005-12-28 Phytopharm Plc Smilagenine et anzurogenine d et leur utilisation
US6867216B1 (en) 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
CA2326654C (fr) * 1998-04-09 2010-11-09 Johns Hopkins University School Of Medicine Utilisation de derives steroides alcaloidiques servant d'inhibiteurs de voies de signalisation "hedgehog"
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
US6344050B1 (en) 1998-12-21 2002-02-05 Light Sciences Corporation Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue
AU2005201269C1 (en) * 1999-01-13 2008-09-04 Curis, Inc. Regulators of the PCT or smoothened pathway, compositions and uses related thereto
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AUPP968699A0 (en) * 1999-04-09 1999-05-06 Cura Nominees Pty Ltd Therapeutic compositions and method for their preparation
TW471968B (en) * 1999-08-25 2002-01-11 Committee On Chinese Medicine Solamargine pharmaceutical composition for killing cancer cells
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
CA2386190C (fr) 1999-10-13 2009-04-14 Johns Hopkins University School Of Medicine Regulateurs du signal hedgehog, compositions et utilisations desdits regulateurs
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
RU2291873C2 (ru) 2000-04-28 2007-01-20 Инфлазим Фармасьютикалз Лимитед 3-амино-6,7-дикислородсодержащие стероиды, фармацевтическая композиция, способы лечения
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
ATE400580T1 (de) * 2001-08-21 2008-07-15 Glycomed Sciences Ltd Chemische synthese von solamargin
JP2005508345A (ja) * 2001-09-28 2005-03-31 グライコメッド・サイエンシーズ・リミテッド 溶媒抽出法
AU2002350513A1 (en) * 2001-10-09 2003-04-22 Glycomed Sciences Limited Use of solasonine for the treatment of skin tumors
WO2003030915A1 (fr) * 2001-10-09 2003-04-17 Glycomed Sciences Limited Utilisation de solamargine pour le traitement de tumeurs de la peau
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
US6984725B2 (en) * 2002-06-28 2006-01-10 Solbec Pharmaceuticals Ltd. Method for the separation of triglycoalkaloids
AUPS329002A0 (en) * 2002-07-01 2002-07-18 Solbec Pharmaceuticals Limited Glycoalkaloid compositions and various uses thereof
AU2003900194A0 (en) * 2003-01-15 2003-01-30 Solbec Pharmaceuticals Limited Methods of modulating il-6
TWI300352B (en) 2003-06-05 2008-09-01 G & E Herbal Biotechnology Co Ltd Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract
CN1329038C (zh) * 2003-06-20 2007-08-01 德英生物科技股份有限公司 茄属植物的水溶性萃取物、其制备方法及其药学组合物
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
US20070149491A1 (en) * 2005-05-17 2007-06-28 Findeis Mark A Compounds useful for treating neurodegenerative disorders
CN101223185A (zh) 2005-05-17 2008-07-16 萨托里医药公司 用于治疗神经变性障碍的化合物
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
AU2007352555B2 (en) * 2006-11-20 2013-04-18 Satori Pharmaceuticals, Inc. Synthesis of compounds useful as modulators of amyloid-beta production
US20100056487A1 (en) * 2006-11-20 2010-03-04 Satori Pharmaceuticals, Inc. Modulators of amyloid-beta production
CN108404129A (zh) * 2012-02-23 2018-08-17 第三共欧洲有限公司 用于调节放射敏感性的her3抑制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR943800A (fr) * 1946-12-31 1949-03-17 Perfectionnements aux projecteurs cinématographiques utilisant des films de format réduit
DE1804331A1 (de) * 1967-10-23 1969-05-22 Erba Carlo Spa Derivate von (25R)-3ss-Amino-5alpha-22alpha-spirostan und Verfahren zu deren Herstellung
DE1900060A1 (de) * 1969-01-02 1970-08-13 Lentia Gmbh Verfahren zur Herstellung von Androstanderivaten
GB1380253A (en) * 1971-01-21 1975-01-08 Inverni Della Beffa Spa Prosapogenins
DE2519261C3 (de) * 1975-04-30 1979-03-01 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Verfahren zur Gewinnung des in den Wurzeln und Rhizomen von Helleborus-Arten enthaltenen Hauptsapogenins
NZ193564A (en) * 1979-05-02 1985-01-31 Aruba Pty Ltd Steroid alkaloids from solanum sodomeum and pharmaceutical compositions
US4937182A (en) * 1985-12-19 1990-06-26 Peralta Cancer Research Institute Method for predicting chemosensitivity of anti-cancer drugs
GB2192185B (en) * 1986-07-03 1991-01-16 Genetic Systems Corp Monoclonal antibodies to pseudomonas aeruginosa flagella
US5227160A (en) * 1988-07-15 1993-07-13 The Biomembrane Institute Monoclonal antibody nuh2 capable of inactivating motility of human sperm, antigen defined by said monoclonal antibody and methods of using said monoclonal antibody and antigen
US5766632A (en) * 1993-10-01 1998-06-16 Legere Pharmaceuticals, Ltd. Method of using lectins for contraception

Also Published As

Publication number Publication date
DE69131861T2 (de) 2000-05-18
KR927003842A (ko) 1992-12-18
JP3168542B2 (ja) 2001-05-21
BR9105952A (pt) 1992-11-17
US5958770A (en) 1999-09-28
KR100213805B1 (en) 1999-08-02
AU7159491A (en) 1991-08-05
CA2073855A1 (fr) 1991-07-19
ATE188036T1 (de) 2000-01-15
WO1991010743A1 (fr) 1991-07-25
DE69131861D1 (de) 2000-01-27
JPH05503847A (ja) 1993-06-24
AU654474B2 (en) 1994-11-10
CA2073855C (fr) 2007-04-24
EP0515386A4 (en) 1993-10-27
EP0515386A1 (fr) 1992-12-02
EP0515386B1 (fr) 1999-12-22

Similar Documents

Publication Publication Date Title
KR100213805B1 (en) Glycoalkaloids
DE69430365D1 (de) Isolierung fötaler erythrozyten
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
AU541099B2 (en) Detection of occult human blood
EP0756633A1 (fr) Procede de traitement de mycobacteries
NL300140I2 (nl) Galanthamine, of verbindingen die eraan analoog zijn, voor behandeling van de ziekte van Alzheimer.
AU4725796A (en) Preparation and use of a specific gaba-A alpha 5 receptor ligand for treatment of Alzheimer's disease
CA2224003A1 (fr) Methode de determination de transfert d'energie resonante par fluorescence servant a identifier la cellule de glycoproteine d'enveloppe de hiv-1
IT8719331A0 (it) Mandrino per il fissaggio di cella per la centrifugazione del sangue, e simili.
Horne et al. Detection of pregnancy specific beta1-glycoprotein in formalin-fixed tissues.
CA2045552A1 (fr) Haptoglobine liee au cancer
YU99683A (en) Process for obtaininga antiulceral 2-guanidino-4-(2subst.amino-2-imidazolyl)-thiaoles
AU7913887A (en) Method for the removal of undesired cells from human lymphocyte populations, application of the method in monoclonal antibody production and kit therefor
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
TNSN86154A1 (fr) Procede pour la preparation de cefodizime
DE69624782D1 (de) Elektrodenzuleitung für implantierbare medizinische Vorrichtung, insbesondere für Herzschrittmacher
AU2087495A (en) Means for treating autoimmune diseases and a method for the treatment thereof
HUT41067A (en) Monoclonal antibodies for the treating of humane lung carcinomes of no small cell type
CA2078861A1 (fr) Dosage permettant d'etablir le contenu total de la chaine peptidique alpha gonadotrope
ES2059539T3 (es) Metodo para la prevencion de la enfermedad del injerto frente al huesped.
SU1167197A1 (ru) Штамм @ @ ИНМИ КС-7,используемый дл очистки сточных вод от 3,4-дихлоранилина
Du Toit et al. High seminal sialic acid concentrations in patients with severe teratozoospermia
IE872567L (en) Treatment of infertility
FR2607257B1 (fr) Procede de traitement biologique par ultrasons, notamment pour tests immuno-hematologiques
AU4459197A (en) Diagnosis aid and process for detecting pregnancy in ruminants